{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:18:25Z","timestamp":1780406305583,"version":"3.54.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>As the most prevalent companion animal, cats are threatened by numerous infectious diseases and carry zoonotic pathogens such as <jats:italic>Toxoplasma gondii<\/jats:italic> and <jats:italic>Bartonella henselae<\/jats:italic>, which are the primary causes of human toxoplasmosis and cat-scratch disease. Vaccines play a crucial role in preventing and controlling the spread of diseases in both humans and animals. Currently, there are only three core vaccines available to prevent feline panleukopenia, feline herpesvirus, and feline calicivirus infections, with few vaccines available for other significant feline infectious and zoonotic diseases. Feline herpesvirus, a major component of the core vaccine, offers several advantages and a stable genetic manipulation platform, making it an ideal model for vaccine vector development to prevent and control feline infectious diseases. This paper reviews the technologies involved in the research and development of the feline herpesvirus vaccine vector, including homologous recombination, CRISPR\/Cas9, and bacterial artificial chromosomes. It also examines the design and effectiveness of expressing antigens of other pathogens using the feline herpesvirus as a vaccine vector. Additionally, the paper analyzes existing technical bottlenecks and challenges, providing an outlook on its application prospects. The aim of this review is to provide a scientific basis for the research and development of feline herpesvirus as a vaccine vector and to offer new ideas for the prevention and control of significant feline infectious and zoonotic diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1445387","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T04:55:19Z","timestamp":1726116919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Advancements, challenges, and future perspectives in developing feline herpesvirus 1 as a vaccine vector"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinru","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/08927936.2022.2125198","article-title":"Older adult companion animal-owner wellbeing during the COVID-19 pandemic: A qualitative exploration","volume":"36","author":"Zablan","year":"2023","journal-title":"Anthrozoos"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ani11082349","article-title":"Companion animal type and level of engagement matter: A mixed-methods study examining links between companion animal guardianship, loneliness and well-being during the COVID-19 pandemic","volume":"11","author":"Clements","year":"2021","journal-title":"Anim (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.619600","article-title":"Variability in human-animal interaction research","volume":"7","author":"Rodriguez","year":"2021","journal-title":"Front Vet Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12917-022-03460-9","article-title":"Development of a triple NanoPCR method for feline calicivirus, feline panleukopenia syndrome virus, and feline herpesvirus type I virus","volume":"18","author":"Ye","year":"2022","journal-title":"BMC Vet Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ani11061842","article-title":"Serological Survey on the Occurrence of Rickettsia spp., Neospora caninum, Bartonella henselae and Toxoplasma gondii in Cats from Tuscany (Central Italy)","volume":"11","author":"Ebani","year":"2021","journal-title":"Anim (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.1999.60.05.652","article-title":"Long-term immunity in cats vaccinated with an inactivated trivalent vaccine","volume":"60","author":"Scott","year":"1999","journal-title":"Am J Vet Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122331","article-title":"Vaccine development: Current trends and technologies","volume":"336","author":"Poria","year":"2024","journal-title":"Life Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities","volume":"9","author":"Ghattas","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","article-title":"Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters","volume":"6","author":"Jia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1884-4_28","article-title":"Plasmodium falciparum antigen expression in leishmania parasite: A way forward for live attenuated vaccine development","volume":"2410","author":"Srivastava","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v12080862","article-title":"Emerging role of mucosal vaccine in preventing infection with avian influenza A viruses","volume":"12","author":"Wang","year":"2020","journal-title":"Viruses"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1522255","article-title":"Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines","volume":"17","author":"Prow","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"BioTechniques"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-77-8-1787","article-title":"Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus","volume":"77","author":"Spitzer","year":"1996","journal-title":"J Gen Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9080619","article-title":"Newcastle disease virus as a vaccine vector for SARS-coV-2","volume":"9","author":"Shirvani","year":"2020","journal-title":"Pathogens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.21775\/cimb.041.469","article-title":"Alphaherpesvirus vaccines","volume":"41","author":"Aschner","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0068123","DOI":"10.1128\/jvi.00681-23","article-title":"Feline herpesvirus 1 (FHV-1) enters the cell by receptor-mediated endocytosis","volume":"97","author":"Synowiec","year":"2023","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1101\/gr.149801","article-title":"Genomewide function conservation and phylogeny in the Herpesviridae","volume":"11","author":"Alb\u00e0","year":"2001","journal-title":"Genome Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF01310650","article-title":"Biochemical study of the Feline Herpesvirus 1. Identification of glycoproteins by affinity","volume":"80","author":"Fargeaud","year":"1984","journal-title":"Arch Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.60.881","article-title":"Properties and functions of feline herpesvirus type 1 glycoproteins","volume":"60","author":"Maeda","year":"1998","journal-title":"J Vet Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-008-0278-4","article-title":"The order herpesvirales","volume":"154","author":"Davison","year":"2009","journal-title":"Arch Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109210","article-title":"Use of feline herpesvirus as a vaccine vector offers alternative applications for feline health","volume":"261","author":"Cottingham","year":"2021","journal-title":"Vet Microbiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/495830","article-title":"Felid herpesvirus type 1 infection in cats: a natural host model for alphaherpesvirus pathogenesis","volume":"14","author":"Maes","year":"2012","journal-title":"ISRN Vet Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2009.00147.x","article-title":"Analysis of herpesvirus host specificity determinants using herpesvirus genomes as bacterial artificial chromosomes","volume":"53","author":"Arii","year":"2009","journal-title":"Microbiol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2020.0034","article-title":"A novel set of cas9 fusion proteins to stimulate homologous recombination: cas9-HRs","volume":"4","author":"Hackley","year":"2021","journal-title":"CRISPR J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.64.10.4930-4938.1990","article-title":"Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins","volume":"64","author":"Cole","year":"1990","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-7-1811","article-title":"The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus","volume":"73","author":"Wardley","year":"1992","journal-title":"J Gen Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s007050170182","article-title":"Further development of a recombinant feline herpesvirus type 1 expressing the Gag protein of feline immunodeficiency virus","volume":"146","author":"Sato","year":"2001","journal-title":"Arch Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ani14060872","article-title":"Protection of chickens against H9N2 avian influenza isolates with a live vector vaccine expressing influenza hemagglutinin gene derived from Y280 avian influenza virus","volume":"14","author":"Zhang","year":"2024","journal-title":"Anim (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01923-23","article-title":"An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice","volume":"98","author":"Nie","year":"2024","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.18.8794","article-title":"Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector","volume":"89","author":"Shizuya","year":"1992","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jare.2022.02.012","article-title":"Direct cloning of a herpesvirus genome for rapid generation of infectious BAC clones","volume":"43","author":"Yuan","year":"2023","journal-title":"J Adv Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2006.07.014","article-title":"Felid herpesvirus 1 glycoprotein G is a structural protein that mediates the binding of chemokines on the viral envelope","volume":"8","author":"Costes","year":"2006","journal-title":"Microbes Infect"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.021","article-title":"Complete genomic sequence and an infectious BAC clone of feline herpesvirus-1 (FHV-1)","volume":"401","author":"Tai","year":"2010","journal-title":"Virology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.virusres.2016.05.001","article-title":"In vitro characterization of felid herpesvirus 1 (FHV-1) mutants generated by recombineering in a recombinant BAC vector","volume":"221","author":"Tai","year":"2016","journal-title":"Virus Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-9525(00)02015-1","article-title":"Forward with BACs: new tools for herpesvirus genomics","volume":"16","author":"Brune","year":"2000","journal-title":"Trends Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116636","article-title":"CRISPR-Cas9 system: A new-fangled dawn in gene editing","volume":"232","author":"Gupta","year":"2019","journal-title":"Life Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-024-01810-7","article-title":"Application of multiple sgRNAs boosts efficiency of CRISPR\/Cas9-mediated gene targeting in Arabidopsis","volume":"22","author":"Li","year":"2024","journal-title":"BMC Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jviromet.2014.11.009","article-title":"Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR\/Cas9 nucleases","volume":"213","author":"Russell","year":"2015","journal-title":"J Virol Methods"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S429411","article-title":"Recent advancements in reducing the off-target effect of CRISPR-cas9 genome editing","volume":"18","author":"Asmamaw Mengstie","year":"2024","journal-title":"Biologics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13110","article-title":"Genome modification by CRISPR\/cas9","volume":"281","author":"Ma","year":"2014","journal-title":"FEBS J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3026","article-title":"Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation","volume":"32","author":"Doench","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(96)00108-9","article-title":"Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector","volume":"14","author":"Willemse","year":"1996","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(96)00131-4","article-title":"Recombinant feline herpesvirus type 1 expressing immunogenic proteins inducible virus neutralizing antibody against feline calicivirus in cats","volume":"14","author":"Yokoyama","year":"1996","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.60.717","article-title":"Further development of a recombinant feline herpesvirus type 1 vector expressing feline calicivirus immunogenic antigen","volume":"60","author":"Yokoyama","year":"1998","journal-title":"J Vet Med Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2023.109978","article-title":"A potential dual protection vaccine: Recombinant feline herpesvirus-1 expressing feline parvovirus VP2 antigen","volume":"290","author":"Yang","year":"2024","journal-title":"Vet Microbiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.008","article-title":"Feline herpesvirus vectored-rabies vaccine in cats: A dual protection","volume":"37","author":"Chen","year":"2019","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410x(95)00205-f","article-title":"Evaluation of subunit vaccines against feline immunodeficiency virus infection","volume":"14","author":"Verschoor","year":"1996","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0168-1702(00)00202-1","article-title":"Efficient expression of the envelope protein of feline immunodeficiency virus in a recombinant feline herpesvirus type 1 (FHV-1) using the gC promoter of FHV-1","volume":"70","author":"Sato","year":"2000","journal-title":"Virus Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s007050050302","article-title":"Construction of a recombinant feline herpesvirus type 1 expressing Gag precursor protein of feline immunodeficiency virus","volume":"143","author":"Sato","year":"1998","journal-title":"Arch Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-1135(99)00096-6","article-title":"Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge","volume":"69","author":"Hesselink","year":"1999","journal-title":"Vet Microbiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-6851(01)00325-5","article-title":"Construction of recombinant feline herpesvirus type 1 expressing Toxoplasma gondii surface antigen 1","volume":"117","author":"Mishima","year":"2001","journal-title":"Mol Biochem Parasitol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s004360100429","article-title":"Recombinant feline herpesvirus type 1 expressing Toxoplasma gondi ROP2 antigen inducible protective immunity in cats","volume":"88","author":"Mishima","year":"2002","journal-title":"Parasitol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1128\/CVI.00034-15","article-title":"Comparative efficacy of feline leukemia virus (FeLV) inactivated whole-virus vaccine and canarypox virus-vectored vaccine during virulent feLV challenge and immunosuppression","volume":"22","author":"Patel","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.17236\/sat00346","article-title":"An update on feline calicivirus","volume":"164","author":"Spiri","year":"2022","journal-title":"Schweiz Arch Tierheilkd"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/v14081602","article-title":"Vaccination and antibody testing in cats","volume":"14","author":"Egberink","year":"2022","journal-title":"Viruses"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/v15081708","article-title":"Feline injection-site sarcoma and other adverse reactions to vaccination in cats","volume":"15","author":"Hartmann","year":"2023","journal-title":"Viruses"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2460\/javma.230.1.52","article-title":"Response of feral cats to vaccination at the time of neutering","volume":"230","author":"Fischer","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"B63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1863-2378.2011.01416.x","article-title":"Risk factors for human rabies in China","volume":"59","author":"Gong","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/v14050923","article-title":"Vaccination of immunocompromised cats","volume":"14","author":"Hartmann","year":"2022","journal-title":"Viruses"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/v10050277","article-title":"Lessons learned in developing a commercial FIV vaccine: the immunity required for an effective HIV-1 vaccine","volume":"10","author":"Sahay","year":"2018","journal-title":"Viruses"},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpara.2020.11.001","article-title":"Control of human toxoplasmosis","volume":"51","author":"Smith","year":"2021","journal-title":"Int J Parasitol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.050","article-title":"Protective effect against toxoplasmosis in BALB\/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine","volume":"42","author":"Li","year":"2024","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.14573\/altex.1807041","article-title":"Animal testing and its alternatives - the most important omics is economics","volume":"35","author":"Meigs","year":"2018","journal-title":"ALTEX"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2013friend or foe","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiol (Reading)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci10010046","article-title":"Epidemiological investigation of feline upper respiratory tract infection encourages a geographically specific FCV vaccine","volume":"10","author":"Gao","year":"2023","journal-title":"Vet Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/vaccines2030581","article-title":"Gene expression driven by a strong viral promoter in MVA increases vaccination efficiency by enhancing antibody responses and unmasking CD8+ T cell epitopes","volume":"2","author":"Becker","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01421-23","article-title":"Several alphaherpesviruses interact similarly with the NF-\u03baB pathway and suppress NF-\u03baB-dependent gene expression","volume":"11","author":"Romero","year":"2023","journal-title":"Microbiol Spectr"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1127","article-title":"Promoters influence the kinetics of transgene expression following adenovector gene delivery","volume":"10","author":"Chen","year":"2008","journal-title":"J Gene Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"106972","DOI":"10.1016\/j.ymgme.2022.107143","article-title":"Novel dual promoter AAV gene therapy platform ensures production of therapeutic soluble lysosomal enzymes with high M6P content to enable broad cellular uptake and cross correction","volume":"138","author":"Hedman","year":"2023","journal-title":"Mol Genet Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8730-6_18","article-title":"Considerations in the use of codon optimization for recombinant protein expression","volume":"1850","author":"Mauro","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/srep24290","article-title":"Construction of recombinant baculoviruses expressing hemagglutinin of H5N1 avian influenza and research on the immunogenicity","volume":"6","author":"Ge","year":"2016","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.32183","article-title":"Optimized Expression, Purification of Herpes B Virus gD Protein in Escherichia coli, and Production of Its Monoclonal Antibodies","volume":"9","author":"Jin","year":"2016","journal-title":"Jundishapur J Microbiol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006857","article-title":"Attenuation of a very virulent Marek\u2019s disease herpesvirus (MDV) by codon pair bias deoptimization","volume":"14","author":"Eschke","year":"2018","journal-title":"PloS Pathog"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2174\/1874357901004030123","article-title":"HSV recombinant vectors for gene therapy","volume":"4","author":"Manservigi","year":"2010","journal-title":"Open Virol J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/375411a0","article-title":"Herpes simplex virus turns off the TAP to evade host immunity","volume":"375","author":"Hill","year":"1995","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.843","article-title":"The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase","volume":"94","author":"He","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/vim.2006.19.391","article-title":"Herpes simplex virus genes Us3, Us5, and Us12 differentially regulate cytotoxic T lymphocyte-induced cytotoxicity","volume":"19","author":"Aubert","year":"2006","journal-title":"Viral Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.03.003","article-title":"Genetic engineering of a modified herpes simplex virus 1 vaccine vector","volume":"27","author":"Liu","year":"2009","journal-title":"Vaccine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.19.9029-9036.2001","article-title":"Recombinant herpes\u00a0simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice","volume":"75","author":"Ghiasi","year":"2001","journal-title":"J Virol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302393","article-title":"Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice","volume":"12","author":"Cui","year":"2005","journal-title":"Gene Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2023.109728","article-title":"Safety and immunogenicity of a TK\/gI\/gE gene-deleted feline herpesvirus-1 mutant constructed via CRISPR\/Cas9 in feline","volume":"281","author":"Yang","year":"2023","journal-title":"Vet Microbiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2022.109387","article-title":"Effective cross-protection of a lyophilized live gE\/gI\/TK-deleted pseudorabies virus (PRV) vaccine against classical and variant PRV challenges","volume":"267","author":"Sun","year":"2022","journal-title":"Vet Microbiol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/v12040369","article-title":"Comparison of gE\/gI- and TK\/gE\/gI-gene-deleted pseudorabies virus vaccines mediated by CRISPR\/cas9 and cre\/lox systems","volume":"12","author":"Li","year":"2020","journal-title":"Viruses"},{"key":"B93","doi-asserted-by":"publisher","first-page":"109104","DOI":"10.1016\/j.vetmic.2021.10910","article-title":"Pathogenicity and immunogenicity of a gI\/gE\/TK\/UL13-gene-deleted variant pseudorabies virus strain in swine","volume":"258","author":"Lv","year":"2021","journal-title":"Vet Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1445387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T04:55:23Z","timestamp":1726116923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1445387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2024.1445387"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1445387","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"article-number":"1445387"}}